Seppro Trademark Details

Seppro was registered on Tuesday, October 18, 2005 and is currently owned by Sigma-Aldrich Co. LLC under the registration number 3007344 . This mark is alive with a status of Registered and Renewed. The last case file activity for this mark occured 8 years ago on Tuesday, September 22, 2015, according to the United State Patent & Trademark Office

Word Mark	Seppro
Status	Alive Registered 800 — Registered and Renewed

Current Owner

Sigma-Aldrich Co. LLC of Saint Louis, MO

View all trademarks for Sigma-Aldrich Co. LLC

Other Trademarks for Sigma-Aldrich Co. LLC

Previous Owners

Sigma-Aldrich Biotechnology Lp of Saint Louis, MO

View all trademarks for Sigma-Aldrich Biotechnology Lp

Other Trademarks for Sigma-Aldrich Biotechnology Lp

Genway Biotech Inc. of San Diego, CA

View all trademarks for Genway Biotech Inc.

Other Trademarks for Genway Biotech Inc.

Serial Number	78359775
Registration Number	3007344
Status Date	Tuesday, September 22, 2015
Filing Date	Tuesday, September 22, 2015
Registration Date	Tuesday, October 18, 2005

Correspondent

KRISTIN J. FROST
SIGMA-ALDRICH CO., LLC
3050 SPRUCE STREET
LAW DEPARTMENT
ST. LOUIS, MO 63103

Case File Statements

Goods & Services	Reagents for fractionating target proteins from complex biological fluids, such as plasma, serum, CSF, urine or other tissue or cellular sources, and the subsequent chemical analysis of compounds physiologically associated with abundant proteins including proteins, peptides, fatty acids, hormones, glycosylation states, phosphorylation states, etc; Reagents for diagnosis of diseases associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Immunoaffinity reagents for developing chemical markers that indicate the presence of disease states associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Reagents for determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions related to albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3 and associated compounds in humans and animals; Reagents for determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3, all for research use
Goods & Services	Product development, medical and laboratory research in the field of proteomics, namely the science, system, components, organization, function, and biomedical applications of separation of abundant proteins, especially, in the area of proteomics sample processing that permits highly selective separation of abundant proteins, such as albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; development of chemical markers that indicate the presence of disease states; determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions in humans and animals; determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets; developing methodologies relating to the previous services such as developing bioanalytical methods to increase sensitivity, specificity and throughput of identifying and characterizing biological substances such as protein, peptides, hormones, lipids, used as biomarkers for a diagnosis or as drug targets

Reagents for fractionating target proteins from complex biological fluids, such as plasma, serum, CSF, urine or other tissue or cellular sources, and the subsequent chemical analysis of compounds physiologically associated with abundant proteins including proteins, peptides, fatty acids, hormones, glycosylation states, phosphorylation states, etc; Reagents for diagnosis of diseases associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Immunoaffinity reagents for developing chemical markers that indicate the presence of disease states associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; Reagents for determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions related to albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3 and associated compounds in humans and animals; Reagents for determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets associated with albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3, all for research use

Product development, medical and laboratory research in the field of proteomics, namely the science, system, components, organization, function, and biomedical applications of separation of abundant proteins, especially, in the area of proteomics sample processing that permits highly selective separation of abundant proteins, such as albumin, IgG, Fibrinogen, Transferrin, IgA, IgM, a2-Macroglobulin, a1-Acid Glycoprotein, a1-Antitrypsin, Haptoglobin, High Density Lipoproteins, Complement C3; development of chemical markers that indicate the presence of disease states; determining biological targets for drugs, namely determining biological processes that are susceptible to being affected by drugs in order that the drugs may alleviate disease states and conditions in humans and animals; determining protein and peptide sequences for the purposes of identifying protein or peptide drug targets; developing methodologies relating to the previous services such as developing bioanalytical methods to increase sensitivity, specificity and throughput of identifying and characterizing biological substances such as protein, peptides, hormones, lipids, used as biomarkers for a diagnosis or as drug targets

Classifications

International Class Codes	001 — Class 1 includes mainly chemical products used in industry, science and agriculture, including those which go to the making of products belonging to other trademark classes. Examples include compost, salt for preserving non-foodstuffs, and certain additives for the food industry.
U.S. Class Codes	001, 005, 006, 010, 026, 046
Status	6 — Active
Status Date	Wednesday, December 8, 2004
First Use Anywhere	Wednesday, January 28, 2004
First Use In Commerce	Wednesday, January 28, 2004
Primary Code	001

International Class Codes	042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes	100, 101
Status	6 — Active
Status Date	Monday, February 9, 2004
First Use Anywhere	Wednesday, January 28, 2004
First Use In Commerce	Wednesday, January 28, 2004
Primary Code	042

Trademark Timeline

Jan 28 2004

First use anywhere for the mark
Jan 28 2004

First use in commerce for the mark
Jan 28 2004

First use anywhere for the mark
Jan 28 2004

First use in commerce for the mark
Jan 29 2004

Trademark application filed with USPTO
Feb 09 2004

New Application Entered In Tram
Aug 20 2004

Assigned To Examiner
Aug 26 2004

Non-Final Action E-Mailed
Dec 01 2004

Correspondence Received In Law Office
Dec 01 2004

Teas Response To Office Action Received
Dec 08 2004

Amendment From Applicant Entered
Jan 10 2005

Examiners Amendment E-Mailed
Jan 10 2005

Examiners Amendment -Written
Jan 11 2005

Approved For Pub - Principal Register
Jan 25 2005

Assigned To Lie
Jan 27 2005

Law Office Publication Review Completed
Apr 22 2005

Withdrawn Before Publication
May 11 2005

Previous Allowance Count Withdrawn
May 13 2005

Approved For Pub - Principal Register
May 13 2005

Examiners Amendment E-Mailed
May 13 2005

Examiners Amendment -Written
May 23 2005

Assigned To Lie
May 26 2005

Law Office Publication Review Completed
Jul 06 2005

Notice of Publication
Jul 26 2005

Published For Opposition
Oct 18 2005

Registered-Principal Register
Oct 18 2005

Trademark officially registered with the USPTO
Mar 11 2009

Automatic Update of Assignment of Ownership
Sep 14 2011

Assignment of Ownership Not Updated Automatically
Oct 04 2011

Attorney Revoked And/or Appointed
Oct 04 2011

Teas Revoke/appoint Attorney Received
Apr 09 2012

Teas Section 8 & 15 Received
Apr 21 2012

Notice of Acceptance of Sec. 8 & 15 - E-Mailed
Apr 21 2012

Registered - Sec. 8 (6-Yr) Accepted & Sec. 15 Ack.
Apr 21 2012

Case Assigned To Post Registration Paralegal
Aug 24 2015

Teas Section 8 & 9 Received
Aug 24 2015

Teas Change of Correspondence Received
Sep 22 2015

Notice of Acceptance of Sec. 8 & 9 - E-Mailed
Sep 22 2015

Registered and Renewed (first Renewal - 10 Yrs)
Sep 22 2015

Registered - Sec. 8 (10-Yr) Accepted/sec. 9 Granted
Sep 22 2015

Case Assigned To Post Registration Paralegal